image
Healthcare - Biotechnology - NASDAQ - US
$ 15.705
-2.76 %
$ 1.01 B
Market Cap
-0.34
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one GLYC stock under the worst case scenario is HIDDEN Compared to the current market price of 15.7 USD, GlycoMimetics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one GLYC stock under the base case scenario is HIDDEN Compared to the current market price of 15.7 USD, GlycoMimetics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one GLYC stock under the best case scenario is HIDDEN Compared to the current market price of 15.7 USD, GlycoMimetics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GLYC

image
$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0$10.0$10.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-32.5 M OPERATING INCOME
17.23%
-37.9 M NET INCOME
-2.66%
-31.1 M OPERATING CASH FLOW
10.84%
20 K INVESTING CASH FLOW
193.62%
5.4 K FINANCING CASH FLOW
-99.98%
0 REVENUE
0.00%
-2.4 M OPERATING INCOME
67.29%
-2.34 B NET INCOME
-32349.35%
-5.11 B OPERATING CASH FLOW
-137844.38%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet GlycoMimetics, Inc.
image
Current Assets 11.1 M
Cash & Short-Term Investments 10.7 M
Receivables 137 K
Other Current Assets 235 K
Non-Current Assets 0
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 0
96.65 %Total Assets$11.1m
Current Liabilities 5.78 B
Accounts Payable 329 K
Short-Term Debt 66.9 M
Other Current Liabilities 5.71 B
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
98.84 %Total Liabilities$5.8b
EFFICIENCY
Earnings Waterfall GlycoMimetics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 40 M
Operating Income -32.5 M
Other Expenses 5.37 M
Net Income -37.9 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)000(40m)(33m)(5m)(38m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-0.71% ROE
-0.71%
-341.52% ROA
-341.52%
0.57% ROIC
0.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis GlycoMimetics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -37.9 M
Depreciation & Amortization 35.2 K
Capital Expenditures -9.97 K
Stock-Based Compensation 4.77 M
Change in Working Capital 1.16 M
Others 2.51 M
Free Cash Flow -31.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets GlycoMimetics, Inc.
image
GLYC has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership GlycoMimetics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
489 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 globenewswire.com - 3 weeks ago
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, Inc. (“Crescent”), along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics' special meeting in lieu of the annual meeting of stockholders held on June 5, 2025 (the “Special Meeting”), including a reverse stock split of GlycoMimetics' common stock to be effected. businesswire.com - 1 month ago
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced that management is scheduled to present at the Jefferies Global Healthcare Conference in New York on Thursday, June 5, 2025, at 11:05 a.m. globenewswire.com - 1 month ago
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics, Inc. (NasdaqGM: GLYC) and Crescent Biopharma, Inc. Pursuant to the terms of the agreement, shareholders of GlycoMimetics will own approximately 3.1% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fai. businesswire.com - 1 month ago
Crescent Biopharma Appoints David Lubner to Board of Directors Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors. globenewswire.com - 2 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders NEW YORK , March 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chimerix, Inc. (NASDAQ: CMRX)'s  sale to Jazz Pharmaceuticals plc for $8.55 per share in cash. If you are a Chimerix shareholder, click here to learn more about your rights and options. prnewswire.com - 4 months ago
Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors globenewswire.com - 4 months ago
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT. prnewswire.com - 7 months ago
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating GlycoMimetics, Inc. (NASDAQ: GLYC ), relating to a proposed merger with First Crescent Biopharma, Inc. Under the terms of the agreement, the pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined Company and the pre-acquisition Crescent stockholders (inclusive of those investors participating in the pre-closing financing) are expected to own approximately 96.9% of the company. globenewswire.com - 8 months ago
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. - GLYC NEW YORK , Nov. 3, 2024 /PRNewswire/ --  Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating GlycoMimetics, Inc. (NASDAQ: GLYC ), relating to a proposed merger with First Crescent Biopharma, Inc. Under the terms of the agreement, the pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined Company and the pre-acquisition Crescent stockholders (inclusive of those investors participating in the pre-closing financing) are expected to own approximately 96.9% of the company. prnewswire.com - 8 months ago
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics, Inc. (NasdaqGM: GLYC) and Crescent Biopharma, Inc. Pursuant to the terms of the agreement, shareholders of GlycoMimetics will own approximately 3.1% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fai. businesswire.com - 8 months ago
8. Profile Summary

GlycoMimetics, Inc. GLYC

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.01 B
Dividend Yield 0.00%
Description GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Contact 9708 Medical Center Drive, Rockville, MD, 20850 https://www.glycomimetics.com
IPO Date Jan. 10, 2014
Employees 4
Officers Mr. Christian B. Dinneen-Long General Counsel & Company Secretary Mr. Shantha Tyavanagimatt Ph.D. Senior Vice President of Technical Operations Mr. Bruce Johnson Senior Vice President & Chief Commercial Officer Ms. Stephanie R. Irish CPA Vice President of Accounting Mr. Chinmaya Rath Senior Vice President & Chief Business Officer